tbuckley/cabot-search huggingface dataset:
Blood flow restriction training in clinical musculoskeletal rehabilitation: a systematic review and meta-analysis
Authors: Luke Hughes, Bruce Paton, Ben Rosenblatt, Conor Gissane, Stephen David Patterson
Journal: British Journal of Sports Medicine (2017)

<h3>Background and objective</h3> Low-load exercise training with blood flow restriction (BFR) can increase muscle strength and may offer an effective clinical musculoskeletal (MSK) rehabilitation tool. The aim of this review was to systematically analyse the evidence regarding the effectiveness of this novel training modality in clinical MSK rehabilitation. <h3>Design</h3> This is a systematic review and meta-analysis of peer-reviewed literature examining BFR training in clinical MSK rehabilitation (Research Registry; researchregistry91). <h3>Data sources</h3> A literature search was conducted across SPORTDiscus (EBSCO), PubMed and Science Direct databases, including the reference lists of relevant papers. Two independent reviewers extracted study characteristics and MSK and functional outcome measures. Study quality and reporting was assessed using the Tool for the assEssment of Study qualiTy and reporting in EXercise. <h3>Eligibility</h3> Search results were limited to exercise training studies investigating BFR training in clinical MSK rehabilitation, published in a scientific peer-reviewed journal in English. <h3>Results</h3> Twenty studies were eligible, including ACL reconstruction (n=3), knee osteoarthritis (n=3), older adults at risk of sarcopenia (n=13) and patients with sporadic inclusion body myositis (n=1). Analysis of pooled data indicated low-load BFR training had a moderate effect on increasing strength (Hedges’ g=0.523, 95% CI 0.263 to 0.784, p&lt;0.001), but was less effective than heavy-load training (Hedges’ g=0.674, 95% CI 0.296 to 1.052, p&lt;0.001). <h3>Conclusion</h3> Compared with low-load training, low-load BFR training is more effective, tolerable and therefore a potential clinical rehabilitation tool. There is a need for the development of an individualised approach to training prescription to minimise patient risk and increase effectiveness.
Time Sequential Transcriptome Analysis Identifies Mir-126 As an Early Biomarker for Inv(16) Acute Myeloid Leukemia (AML) Disease Progression
Authors: Jing Qi, Guerry J Cook, Bin Zhang, Wei-Kai Hua, Cai Qi, Emily Carnahan, Ayelet Marom, Le Xuan Truong Nguyen, Yang Lu, Sergio Branciamore, Herman Wu, Yate-Ching Yuan, Xiwei Wu, Ling Li, Anthony S. Stein, Russell Rockne, Marcin Kortylewski, Guido Marcucci, Ya-Huei Kuo
Journal: Blood (2016)
Frequency of late-stage breast cancer diagnoses despite high mammography screening rates in an HMO
Authors: R. Haque, J. E. Schottinger, M. H. Kanter, C. C. Avila, R. Contreras, M. A. Gordon, V. P. Quinn
Journal: Journal of Clinical Oncology (2009)

1526 Background: Kaiser Permanente Southern California (KPSC) led the nation in screening women for breast cancer (BCa) with a mammography rate of nearly 90% in 2007 according to 2008 Healthcare Effectiveness Data and Information Set (HEDIS) measures. Despite successes in improving screening rates in this health plan that serves 3+ million diverse members, the percentage of women diagnosed with late stage BCa (stage III, IV) remained stable, varying from 12.9% (N∼323) in 2003 to 10.8% (N∼270) in 2007. To identify patient and health care factors associated with late stage diagnosis and the impact of its enhanced screening implementation guidelines, KPSC undertook this study. Methods: This cross-sectional study included a cohort of 10,580 BCa patients from 2003–2007. We compared women diagnosed with late stage disease versus those with early stage disease (stages I, II). P values (2-sided) were based on the chi-square distribution. Adjusted odds ratios and 95% confidence intervals were estimated using unconditional logistic regression. Results: Factors that were positively associated with late stage diagnosis in the univariate analyses included age, lack of recent mammography screening, worse tumor features, 80+ years of age, minority race, lower geocoded household income, increased healthcare visits, and use of Pap testing (P &lt; 0.01 for all variables). Factors significantly associated with late stage diagnosis in the multivariate model included only lack of recent mammography screening (OR = 1.35, 95% CI: 1.14–1.58) and worse tumor features including high grade (grade 3, OR = 2.58, 95% CI: 1.96–3.40), positive lymph nodes (OR = 53.49, 95% CI: 39.90–71.72), and HER-2+ tumors (OR = 1.40, 95% CI: 1.13–1.72). Conclusions: Targeting older women, those with lower utilization, and women who did not have a recent mammogram may help further lower the prevalence of late stage diagnoses. However, given the extent of the health plan's previous efforts to enhance BCa screening rates, a ceiling effect may limit additional benefit. Additional efforts to decrease the rate of advanced tumor stage at diagnosis may include improving interpretation of mammograms or earlier detection of aggressive tumors by enhanced BRCA genetic testing. No significant financial relationships to disclose.
Enhanced Protein Translation Underlies Improved Metabolic and Physical Adaptations to Different Exercise Training Modes in Young and Old Humans
Authors: Matthew M. Robinson, Surendra Dasari, Adam R. Konopka, Matthew L. Johnson, S. Manjunatha, Raul Ruiz Esponda, Rickey E. Carter, Ian R. Lanza, K. Sreekumaran Nair
Journal: Cell Metabolism (2017)
PP51. SURGICAL CHALLENGES OF PRESERVING QUALITY OF LIFE IN POSTERIOR MEDIOBASAL TEMPORAL LOW AND HIGH GRADE GLIOMAS. ANATOMICAL WHITE MATTER FIBER DISSECTION STUDY AND VIDEO ANALYSIS OF THE POSTERIOR SUBTEMPORAL APPROACH
Authors: Mr Christian Brogna, Mr Francesco Vergani, Mr Richard Gullan, Prof Keyoumars Ashkan, Mr Ranj Bhangoo
Journal: Neuro-Oncology (2017)

OBJECTIVES: Anatomical and surgical analysis of the posterior subtemporal approach to address intrinsic lesions of the posterior mediobasal temporal region while preserving cortical and subcortical structures related to language functions and integrity of optic pathways. SUBJECTS: 10 cadaveric hemispheres were dissected according to Klinger’s technique to reveal the anatomy of the optic pathways, tapetum fibers and of the mediobasal temporal region. Video analysis of two patients harbouring a low grade and high grade glioma in the posterior mediobasal temporal region in the dominant and non-dominant hemisphere respectively. METHODS: Electronic datas, intraoperative video and imaging reviewed with 3D VP Reveal platform and feasibility of the approach analysed. Datas collected were reviewed according to the anatomical findings in the cadaveric specimens. RESULTS AND CONCLUSION: The subtemporal approach allows microsurgical access to the mediobasal temporal region providing good surgical exposure to perform an adequate resection of both low and high grade gliomas, while preserving structures related to vision and language functions, therefore preserving quality of life. Differently from the anterior temporal region, the posterior temporal region is located above the petrous ridge and tentorium proving a flat antero-posterior and latero-medial basal cisternal corridor to the mediobasal structures, anterior or posterior to the vein of Labbe’ complex. Mastering cortical and subcortical anatomy of the posterior temporal region, relationships of the collateral sulcus with the trigone as well as the anatomy of the venous system is the conditio sine qua non for a safe removal of posterior mediobasal temporal gliomas.
Abstract MS1-2: MS1-2 Breast cancer immunotherapy: Building on clinical success
Authors: LA Emens
Journal: Cancer Research (2017)

Abstract Breast cancer has long been considered immunologically silent, but it is now clear that the immune system is active in this disease. Breast cancers can naturally induce tumor infiltrating lymphocytes (TIL), which represent a biomarker of the endogenous immune response. Increasing data support the association of TIL with a better prognosis for breast cancer patients, and also suggest that the presence of TIL can predict response to standard breast cancer therapies. These observations have stimulated intense interest in harnessing the natural breast cancer-specific immune response for therapeutic benefit. Breast cancer vaccines that activate the breast cancer-specific immune response have been tested for many years, with minimal clinical success to date. This is likely due to both inadequate vaccination platforms and dominant mechanisms of immune suppression active within the breast tumor microenvironment. In the tumor microenvironment, the immune checkpoint pathway governed by the programmed cell death-1 (PD-1) receptor and its ligand PD-L1 has emerged as a significant mechanism of immune resistance in a variety of cancers, including breast cancer. Several monoclonal antibody antagonists of PD-1 or PD-L1 unleash the activity of tumor-specific T cells in multiple types of cancer, resulting in durable clinical responses that translate into an overall survival benefit. Early data in breast cancer reveal that these agents have activity in some patients with triple negative and estrogen receptor-positive breast cancer, with response rates that range from about 5-44%. Antagonists of the PD-1 pathway are typically well-tolerated in breast cancer patients, with unique immune-related adverse events that are quite manageable. Selecting patients for PD-L1 expression appears to enrich for responders to single agent therapies that target PD-1/PD-L1. Based on early clinical data, agents that target the PD-1 pathway are under accelerated clinical development for breast cancer treatment. The challenge moving forward is converting immunotherapy non-responders to responders. Combination immunotherapies that integrate standard breast cancer therapies and/or multiple innovative immune-based therapies to simultaneously promote T cell activity and relieve multiple mechanisms of immune suppression at the tumor site have the greatest potential for enhancing the clinical activity of immunotherapy for breast cancer patients. Citation Format: Emens LA. MS1-2 Breast cancer immunotherapy: Building on clinical success [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr MS1-2.
The Cost of Pediatric Unrelated Donor Transplantation
Authors: Daniele Porto Barros, Adriana Seber, Fernando Domingues, Luciana Antunes, Valeria Araujo, Olga Felix, Adriane Ibanez, Victor Zecchin, Roseane Gouveia, Valeria Cortez Ginani, Antonio Sérgio Petrilli, Carmen Vergueiro
Journal: Blood (2012)
Bleeding near brain is linked to increased use of anti-clotting drugs, study finds
Authors: Jacqui Wise
Journal: BMJ (2017)

The risk of subdural haematoma is associated with antithrombotic drug use, particularly a vitamin K antagonist, a large Danish study has found.1

Although use of antithrombotic drugs has long been recognised as a risk factor for subdural haematoma, previous studies were either based exclusively on patients with subdural haematoma and no comparison group or focused exclusively on patients treated with an anticoagulant.

The researchers used a Danish registry to identify 10 010 patients …
Constitutional Loss-of-Function Mutations in Telomerase Are Genetic Risk Factors for Acute Myeloid Leukemia.
Authors: Rodrigo T. Calado, Joshua A. Regal, William T. Yewdell, Roberto P. Falcao, Leandro Figueiredo, Elihu H. Estey, Marco A. Zago, Mark Hills, Stephen J. Chanock, Peter M. Lansdorp, Neal S. Young
Journal: Blood (2007)
Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register
Authors: Elisabeth Lie, Ulf Lindström, Tatiana Zverkova-Sandström, Inge C Olsen, Helena Forsblad-d'Elia, Johan Askling, Meliha C Kapetanovic, Lars Erik Kristensen, Lennart T H Jacobsson
Journal: Annals of the Rheumatic Diseases (2017)

Tumour necrosis factor-α inhibitor (TNFi) treatment has been shown to reduce the rates of anterior uveitis (AU) in patients with ankylosing spondylitis (AS). Our objective was to compare the effect of adalimumab (ADA), etanercept (ETN) and infliximab (IFX) on AU occurrence in AS, using real-world data.Patients with AS starting ADA, ETN or IFX as their first TNFi from January 2003 to December 2010 were extracted from the Swedish Rheumatology Quality Register. AU rates, based on visits to an ophthalmologist with International Classification of Diseases 10 codes for AU, were obtained by linkage to the Swedish National Patient Register. For each TNFi, AU rates 2 years before TNFi start and for the first 2 years on TNFi treatment were compared. In the subgroup of patients who were AU-free during the 2 years before TNFi start, we also compared the risk of a first AU event.1365 patients with AS were included (406 ADA, 354 ETN, 605 IFX). Compared with pretreatment rates, we noted a reduction in overall AU rates for ADA and IFX, and an increase for ETN. The adjusted HRs for AU in 1127 patients who were free of AU in the last 2 years before TNFi start were significantly higher for ETN versus ADA (HR: 3.86 95% CI 1.85 to 8.06) and ETN versus IFX (HR: 1.99, 95% CI 1.23 to 3.22), while the HR for IFX versus ADA was not statistically significant.The results suggest differences in effect on AU risk between ADA, ETN and IFX, with a clear advantage for ADA/IFX over ETN.
Clinical and histopathological risk associated with brain metastasis-free survival in breast cancer.
Authors: Serafin Morales, Ariadna Gasol Cudós, Antonieta Salud, Noemí Tuset Der-abrain, Juan Felipe Cordoba Ortega, Antonia Salud
Journal: Journal of Clinical Oncology (2015)

e11551 Background: Brain metastases (BM) are usually a late event process in metastatic breast cancer. Brain metastases free survival (BMFS) is defined as the interval from diagnosis of extracranial breast cancer metastases until diagnosis of brain metastases. Methods: We aimed to determine clinical and histopathological risk factors associated with early development of 65 breast cancer patients who developed BM during follow-up between 2004 and 2014 in a single institution. Results: 47 patients had locally-advanced disease at the time of diagnosis, and 11 had already metastatic disease. None of early breast cancer patients had BM as the first site of metastases (0/25), however those with locally advanced (15/25) or stage-IV (10/25) at diagnosis presented with BM as the first site of metastasis. The median BMFS was 40 months (7-294m); even if the first relapse was central nervous system, it was 30m versus 81m if brain was not the first metastatic site (p = 0,000, HR 3,34). The estrogen receptor negative status was the only factor analyzed associated with a shorter BMFS (44 months vs 84 months, p = 0,002). Within patients with BM as the first metastases none size, lymph nodes nor lung and liver metastases could predict a shorter BMFS; only estrogenic receptor negative was associated with BM as the first metastatic site (p = 0,045). The lower size (HR 0,8, p = 0,02) and estrogenic receptor expression (HR 0,99, p = 0,02) could have an association with a longer BMFS. Conclusions: Time from diagnosis to brain metastases and central nervous system as the first site of metastatic disease, are crucial to prognosis of BM in breast cancer. The estrogen receptor negative is the most important factor to predict a shorter BMFS in our series. Further studies are needed to identify a high-risk population of BM deriving the largest benefit from screening and prevention.
Successful Allogenic Bone Marrow Transplantation in Man: Chimerism, Induced Specific Tolerance and Possible Anti-Leukemic Effects
Authors: G. MATHÉ, J. L. AMIEL, L. SCHWARZENBERG, A. CATTAN, M. SCHNEIDER, M. J. DE VRIES, M. TUBIANA, C. LALANNE, J. L. BINET, M. PAPIERNIK, G. SEMAN, M. MATSUKURA, A. M. MERY, V. SCHWARZMANN, A. FLAISLER
Journal: Blood (1965)
Intrapleural Rituximab (R) Is Effective in Refractory Pleural Effusion Due to Non- Hodgkin’s Lymphoma
Authors: Silvia Rivas-Vera, Carlos Cadena-Eumaña, Juan Chalapud-Revelo, Adriana Aguilar-Navarro, Pedro Sobrevilla-Calvo, Cristina Lievano-Torres
Journal: Blood (2008)
CC-486 (Oral Azacitidine) Monotherapy in Patients with Acute Myeloid Leukemia (AML)
Authors: Michael R. Savona, Steven D. Gore, Kathryn S. Kolibaba, Stacey M. Ukrainskyj, Keshava Kumar, Qian Dong, Joel Hetzer, Barry Skikne, Guillermo Garcia-Manero
Journal: Blood (2015)
Fludarabine, Cytarabine, and Attenuated-Dose Idarubicin (m-FLAI) Induction for Elderly Patients with Acute Myeloid Leukemia: Results of a Multicenter Phase II Study,
Authors: Yoojoo Lim, Youngil Koh, Sung-Soo Yoon, Seonyang Park, Byoung Kook Kim, Dae-Young Kim, Jung-Hee Lee, Kyoo-Hyung Lee, June-Won Cheong, Hyuk Kim, Young Don Joo, Jong-Ho Won, Sung-Kyu Park, Se Hyung Kim, Dae Sik Hong, Eunkyung Park, Min Kyoung Kim, Sang Kyun Sohn, Sung Hyun Kim, Hong-Kee Lee, Chul Soo Kim, Elihu H. Estey, Je-Hwan Lee, Yoo-Hong Min, Inho Kim
Journal: Blood (2011)
Financial relationships with commercial interests (COI) among abstracts at the ASCO Annual Meeting.
Authors: Angela R. Bradbury, Beverly Moy, Jeffrey M. Peppercorn, Brian Egleston, Colleen B. Sands, Moktar Sheikh-Salah, Courtney D. Storm, Paul R. Helft
Journal: Journal of Clinical Oncology (2012)

6128 Background: ASCO has a formal policy that requires disclosure of COI with entities having a commercial interest in research. There are limited data describing the frequency and type of COI reported in cancer research and how these have changed over time. Methods: We reviewed author-reported COI for abstracts submitted for the ASCO Annual Meeting in 2006 and 2008–2011. COI are classified as employment, stock, consultant, honoraria, research, expert witness, and other. Logistic regression models were used to evaluate the association between COI and acceptance at the annual meeting and change over time. Results: 37% of all abstracts reported at least one author with a COI. Any COI increased significantly from 33% in 2006 to 39% in 2011 (p&lt;0.001). Any COI and all categories of COI were significantly more prevalent among abstracts accepted for presentation compared to those accepted for publication only (Table). Among abstracts accepted for presentation, any COI increased from 39% in 2006 to 48% in 2011 (p&lt;0.001) Increases by year were statistically significant for overall (p&lt;0.001), honoraria (p=0.045), and research (p=0.002) COI. Conclusions: Many authors submitting abstracts accepted for presentation at the ASCO Annual Meeting disclose COI. Reported COI have increased over time and are significantly more frequent among abstracts accepted for presentation than for publication only. These data suggest either that cancer research increasingly involves relationships with industry or that COI reporting has become more common. Policies to manage and foster these relationships will continue to be required and revised. [Table: see text]
Fitness in Young Adulthood and Long-Term Cardiac Structure and Function
Authors: Ambarish Pandey, Norrina B. Allen, Colby Ayers, Jared P. Reis, Henrique T. Moreira, Stephen Sidney, Jamal S. Rana, David R. Jacobs, Lisa S. Chow, James A. de Lemos, Mercedes Carnethon, Jarett D. Berry
Journal: JACC Heart Failure (2017)
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial
Authors: Evan W Alley, Juanita Lopez, Armando Santoro, Anne Morosky, Sanatan Saraf, Bilal Piperdi, Emilie van Brummelen
Journal: The Lancet Oncology (2017)
Phase I study of olaparib in combination with carboplatin and/or paclitaxel in patients with advanced solid tumors.
Authors: Ruud van der Noll, Joo Ern Ang, Agnes Jager, Serena Marchetti, Marja Mergui-Roelvink, Johann Sebastian De Bono, Martijn Lolkema, Andre Brunetto, Hendrik-Tobias Arkenau, Maja J. De Jonge, Diane van der Biessen, Ilian Tchakov, Karin Bowen, Jan H. M. Schellens
Journal: Journal of Clinical Oncology (2013)

2579 Background: This three-center phase I study evaluated the PARP1/2 inhibitor olaparib (O) in combination with carboplatin (C), paclitaxel (Pa) or both (CPa) in patients (pts) with advanced solid tumors refractory to standard therapies (NCT00516724). Methods: This ongoing study consists of multiple parts (P) in which escalating doses of O capsule and tablet formulations were studied. Capsule formulation data are presented; continuous O with C (P1; 21 day cycle), CPa (P2a; 21 day cycle) and weekly Pa (P2b; 28 day cycle) or intermittent O with CPa (P3; 21 day cycle). Primary and secondary objectives were safety/tolerability and antitumor activity (RECIST), respectively. Results: This analysis (non validated data) included 87 enrolled pts (P1 [n=25] P2a [n=20] P2b [n=12] and P3 [n=30]). Most common tumor types were breast (26%), melanoma (10%) and ovarian (7%). 12 pts had known gBRCA1/2 mutations. A tolerable continuous dosing schedule of O with CPa was not determined. Most common AEs (all grades) were myelosuppression (71%) notably neutropenia (54%) and thrombocytopenia (26%), and fatigue (77%). Excessive treatment cycle delays due to hematologic toxicity occurred with continuous O combined with standard doses of C or CPa. Two doses were identified as tolerable: continuous O 100 mg bd with weekly Pa 80 mg/m 2 and intermittent O 200 mg bd (d1–10) with CPa AUC4/175 mg/m 2 q 3 weeks. 14/87 pts (16%) had an objective response (complete response [CR] 5%; partial response [PR] 11%); 28% had stable disease for ≥4 months. Activity appeared greater in pts with BRCA1/2 mutations (CR 17%; PR 33%). Conclusions: Continuous O in combination with CPa exacerbated hematologic toxicities leading to schedule delays. Tolerability improved with intermittent O. Antitumor activity was highest in pts with a BRCA1/2 mutation. This study identified two tolerable O capsule treatment schedules for further development. Clinical trial information: NCT00516724. [Table: see text]